Compare ARK Genomic Revolution ETF (ARKG) vs KeyCorp (KEY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs KeyCorp — how do they compare? ARK Genomic Revolution ETF trades at $41, while KeyCorp trades at $23.31 (market cap $25.15B). The key difference: KeyCorp pays a 3.52% dividend while ARK Genomic Revolution ETF pays none, and KeyCorp is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | KEY | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $23.43 |
52-Week Low | $23.09 | $16.78 |
Market Cap | — | $25.15B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
KeyCorp (KEY) trades at $23.30, up 0.87% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.42. Revenue rebounded to $7.29 billion in 2025, driving net income to $1.83 billion. Analyst consensus is strongly positive, with a $29.32 price target representing significant upside. Recent news highlights a new $3 billion share buyback program and innovations in business fraud protection.
The outlook for KEY is favorable, supported by earnings momentum, shareholder returns, and analyst optimism. Key opportunities include continued earnings beats and capital return initiatives. Risks involve volatile cash flows, with net cash flow negative in 2025 and 2026, and sensitivity to interest rate changes affecting bank profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
